Press Releases: Molecular Imaging

Select a different year:

Siemens’ New Biograph mCT PET•CT System Enables Greater Diagnostic Certainty

November 27, 2011

Chicago, November 27, 2011 – At the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 27 to December 2, Siemens Healthcare (Booth #822, East Building/Lakeside Center at McCormick Place, Hall D) introduced the next-generation Biograph mCT, a positron emission tomography/computed tomography (PET•CT) scanner that enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the new PET•CT result in quantitative assessments that are accurate and consistent. With the new Biograph mCT, Siemens presents another paradigm in PET•CT, further strengthening the company’s innovative power and competitiveness – a goal of its recently introduced global initiative, Agenda 2013. More

Siemens Offers Imaging Innovation and Affordable High-end Performance at RSNA 2011

November 27, 2011

Chicago, November 27, 2011 – At the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), from November 27 to December 2 in Chicago, Siemens Healthcare (Booth #822, East Building/Lakeside Center at McCormick Place, Hall D) again leads the way in medical imaging innovation by offering industry-redefining advancements in computed tomography, molecular imaging, ultrasound technology and more – while demonstrating an increasing cost consciousness that expands the availability of its cutting-edge systems to a wider range of customers than ever before. More

Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly’s Molecular Imaging Agent

November 7, 2011

Malvern, Pa., and Knoxville, Tenn., November 7, 2011 – PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., has entered into a nationwide commercial agreement with Eli Lilly and Company that grants Siemens PETNET Solutions the right to manufacture and distribute Lilly’s molecular imaging agent that is currently under review by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging. More

Siemens PETNET Solutions Opens University of Va. Imaging Biomarker Manufacturing and Nuclear Pharmacy Facility

October 14, 2011

Knoxville, Tenn., Oct. 14, 2011 – PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., has expanded its positron emission tomography (PET) services in the Virginia/Maryland area with the September 8 opening of its cyclotron-equipped manufacturing facility and PET nuclear pharmacy on the University of Virginia (UVA) campus in Charlottesville. The new facility, which PETNET Solutions operates in conjunction with UVA, will provide radiopharmaceuticals for oncology, cardiology and neurology. More

Siemens Completes Phase II Trial for PET Biomarker

September 28, 2011

Malvern, Pa., Sept. 28, 2011 – The Molecular Imaging Biomarker Research Group of Siemens Medical Solutions USA, Inc., recently completed a Phase II multi-center clinical trial of its HX4 positron emission tomography (PET) imaging biomarker, which is designed to detect hypoxia – a reduction in tissue oxygen levels – in solid tumors. The trial’s primary objective was to test the reproducibility of HX4’s uptake in tumors by conducting PET/computed tomography (CT) scans of the same patient on sequential days in a test-retest protocol. The trial enrolled 40 patients with head and neck, lung, liver, rectal or cervical cancers, who were scheduled to receive chemotherapy, radiation therapy or a combination of the two. More

Siemens Unveils Inveon Research Workplace 4.0, Inveon Viewer Software at World Molecular Imaging Congress

September 7, 2011

San Diego, Sept. 7, 2011 – At the World Molecular Imaging Congress (WMIC) 2011, Sept. 7-10 in San Diego, Siemens Healthcare Molecular Imaging (Booth #302) will unveil its revolutionary Inveon Research Workplace (IRW) 4.0, the newest version of its image visualization and analysis software package for preclinical imaging applications, which incorporates multiple enhancements to address the expanding scope and complexity of small animal imaging. Also at WMIC 2011, Siemens will launch its new Inveon Viewer software, which enables superior collaboration and increased consistency in quantitative analysis. Both software offerings greatly advance workflow efficiency and overall productivity in preclinical imaging. Additionally, Siemens will announce a compatibility agreement with third-party software providers PMOD Technologies and Ottawa Heart Institute that expands the compatibility of Siemens’ IRW 4.0 software. More

Siemens’ Biograph mMR receives FDA 510(k) Clearance

June 10, 2011

Malvern, Pa. June 10, 2011 – The U.S. Food and Drug Administration (FDA) recently granted Siemens Healthcare 510(k) clearance for the Biograph mMR, the first system worldwide to enable simultaneous whole-body acquisition of data from magnetic resonance (MR) and positron emission tomography (PET). More

Biograph mCT 20 Excel Offers Affordable, High-Quality PET•CT

June 6, 2011

San Antonio, June 6, 2011 – This year at SNM ’11, Siemens Healthcare (booth #6033) will introduce Biograph mCT 20 Excel, on display for the first time in a nuclear medicine-focused meeting. Biograph mCT 20 Excel is the latest addition to the Biograph™ family of PET•CT imagers. A world leader in molecular imaging innovation, this hybrid system offers outstanding imaging performance at a lower cost--a state-of-the-art 20-slice molecular CT scanner that fits customer budgets without compromising clinical performance. More

At SNM 2011, Siemens Demonstrates Solution for Expanding Clinical Utilization in Nuclear Cardiology

June 6, 2011

San Antonio, June 4, 2011 – At SNM ‘11, June 4-8, Siemens Healthcare (booth #6033) will demonstrate how users of the Symbia S and Symbia T series, single-photon emission computed tomography (SPECT) and SPECT•CT systems, respectively, are taking advantage of IQ•SPECT, to dramatically reduce the length of imaging protocols. A field-upgradeable combination of hardware and software, IQ•SPECT is helping nuclear cardiologists cut the cardiac imaging protocol from approximately 20 minutes to less than five minutes. These shortened exams enable a sustainable approach to nuclear cardiology that potentially enables decreased radiation dose to patients, assists to make the procedure more tolerable for the elderly, provides high quality diagnostic information, and allows users to better utilize an imaging resource that is hampered by limited availability of the key radiotracer. More

Siemens Expands Customer Return on Innovation at SNM 2011

June 3, 2011

San Antonio, June 3, 2011 – At the 2011 SNM Annual Meeting in San Antonio, Siemens Healthcare (booth #6033) will address the increasing demand for molecular imaging procedures and Siemens’ efforts to expand molecular imaging’s availability in three directions: patient access, clinical utilization, and new clinical applications. Through this benchmark-redefining growth of molecular imaging, Siemens is “Expanding Your Return on Innovation.” More

At ACC 2011, Siemens Demonstrates Solution for Ultrafast Nuclear Cardiology

April 4, 2011

New Orleans, April 4, 2011 — Siemens Healthcare will demonstrate how users of the Symbia S and Symbia T series, SPECT and SPECT•CT systems, respectively, are taking advantage of IQ•SPECT, to dramatically reduce the length of imaging protocols. A field-upgradeable combination of hardware and software, IQ•SPECT is helping nuclear cardiologists cut the cardiac imaging protocol from 20 minutes to less than five minutes. These shortened exams enable a sustainable approach to nuclear cardiology that potentially enables decreased radiation dose to patients, assists to make the procedure more tolerable for the elderly, provides high quality diagnostic information, and allows users to better utilize an imaging resource that is hampered by limited availability of the key radiotracer. More

PETNET Solutions Receives FDA Approval for Fludeoxyglucose F 18 Injection, USP

March 9, 2011

Knoxville, Tenn., March 9, 2011 – PETNET Solutions, Inc. a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. announced today the approval of an Abbreviated New Drug Application (ANDA) for Fludeoxyglucose F 18 Injection, USP ([18F]FDG). PETNET Solutions’ submission of an ANDA, well in advance of regulatory requirements for the positron emission tomography (PET) radiopharmaceutical industry, reinforces its industry leadership in manufacturing and distribution of [18F]FDG. Siemens PETNET Solutions is the first commercial manufacturer and distributor to achieve approval of an ANDA for [18F]FDG. More

PETNET Solutions Assists NCI/NIH in Facilitating FDA Approval for Their NDA for Sodium Fluoride F18 Injection

February 8, 2011

Knoxville, Tenn., February 8, 2011 – In an announcement by the National Cancer Institute (NCI) and the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for use of a new strength of a previously approved drug, sodium fluoride F 18 (18F-NaF) injection, for use in bone scans. PETNET Solutions, Inc. a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. is the only commercial manufacturer to be included in this NDA for 18F-NaF injection, at this time. More